NCT05783596View on ClinicalTrials.gov

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2029

Conditions
Follicular LymphomaMarginal Zone LymphomaIndolent Non-hodgkin Lymphoma
Interventions
DRUG

Obinutuzumab

Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.

DRUG

Glofitamab

T-cell bispecific humanized monoclonal antibody, via IV infusion.

Trial Locations (4)

10032

Columbia University Irving Medical Center, New York

10128

Mount Sinai Medical Center, New York

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Reid Merryman, MD

OTHER